Advertisement

Association of Low-Density Lipoprotein Testing After an Atherosclerotic Cardiovascular Event with Subsequent Statin Adherence and Intensification

Published:November 30, 2021DOI:https://doi.org/10.1016/j.amjmed.2021.11.011

      Abstract

      Purpose

      This study aimed to evaluate associations between outpatient low-density lipoprotein cholesterol (LDL-C) testing and subsequent statin adherence and intensification in patients after an atherosclerotic cardiovascular (ASCVD) event.

      Methods

      This was a longitudinal study of adult members of Kaiser Permanente Northern California hospitalized with an ASCVD event (myocardial infarction or stroke) during January 01, 2016, to December 31, 2017, with follow-up through December 31, 2019. Outcomes were statin adherence (estimated using continuous medication gap [CMG]) and intensification (defined by an increased dose or switch to a higher-intensity statin) based on pharmacy dispensing. The exposure of interest was first outpatient LDL-C test after an ASCVD event. Baseline for follow-up was LDL-C test date or a date assigned using incidence density sampling. Multivariate logistic regression models were specified to estimate the odds ratios for statin adherence or intensification among those with vs without an LDL-C test, with adjustment for age, sex, race/ethnicity, smoking, hypertension, diabetes, body mass index, and estimated glomerular filtration rate.

      Results

      There were 19,604 adults hospitalized with ASCVD, including 7054 adults not on high-intensity statins. The mean age was 69.5 years and 33.0% were female. Prevalence of good adherence (continuous medication gap ≤20%) was significantly higher (80.2% vs 75.9%; odds ratio 1.38; 95% confidence interval, 1.28-1.49; P <.001) among participants who had an LDL-C test compared with participants who did not. LDL-C testing was associated with significantly higher rates of treatment intensification (16.1% vs 10.7%; odds ratio 1.51; 95% confidence interval,1.29-1.76; P <0.001).

      Conclusions

      Low-density lipoprotein cholesterol testing is recommended for patients with a history of ASCVD and may be a high-value and low-cost intervention to improve adherence and statin management.

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to The American Journal of Medicine
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Stone NJ
        • Robinson JG
        • Lichtenstein AH
        • et al.
        American College of Cardiology/American Heart Association Task Force on Practice Guidelines. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines.
        J Am Coll Cardiol. 2014; 63: 2889-2934
        • Grundy SM
        • Stone NJ
        • Bailey AL
        • et al.
        2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol: A Report of the ACC/AHA Task Force on Clinical Practice Guidelines.
        J Am Coll Cardiol. 2019; 73: e285-e350
        • Virani SS
        • Pokharel Y
        • Steinberg L
        • et al.
        Provider understanding of the 2013 ACC/AHA cholesterol guideline.
        J Clin Lipidol. 2016; 10: 497-504.e4
        • Drozda Jr, JP
        • Ferguson Jr, TB
        • Jneid H
        • et al.
        2015 ACC/AHA focused update of secondary prevention lipid performance measures: report of the American College of Cardiology/American Heart Association Task Force on Performance Measures.
        J Am Coll Cardiol. 2016; 67: 558-587
        • Jneid H
        • Addison D
        • Bhatt DL
        • et al.
        2017 AHA/ACC clinical performance and quality measures for adults with ST-elevation and non-ST-elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Performance Measures.
        J Am Coll Cardiol. 2017; 70: 2048-2090
        • Steiner JF
        • Koepsell TD
        • Fihn SD
        • Inui TS.
        A general method of compliance assessment using centralized pharmacy records. Description and validation.
        Med Care. 1988; 26: 814-823
        • Steiner JF
        • Prochazka AV.
        The assessment of refill compliance using pharmacy records: methods, validity, and applications.
        J Clin Epidemiol. 1997; 50: 105-116
        • Raebel MA
        • Schmittdiel J
        • Karter AJ
        • Konieczny JL
        • Steiner JF.
        Standardizing terminology and definitions of medication adherence and persistence in research employing electronic databases.
        Medical Care. 2013; 51: S11-S21
      1. Schmittdiel JA, Nichols GA, Dyer W, Steiner JF, Karter AJ, Raebel MA. Health care system-level factors associated with performance on Medicare STAR adherence metrics in a large, integrated delivery system. 2015;53(4):332-337.

        • Nieuwlaat R
        • Wilczynski N
        • Navarro T
        • et al.
        Interventions for enhancing medication adherence.
        Cochrane Database Syst Rev. 2014; CD000011
        • Rana JS
        • Parker MM
        • Liu JY
        • Moffet HH
        • Karter AJ.
        Adherence to cardio-protective medications prescribed for secondary prevention after an acute coronary syndrome hospitalization compared to usual care.
        J Gen Intern Med. 2018; 33: 1621-1622
        • Ridker PM
        • Mora S
        • Rose L
        • JUPITER Trial Study Group
        Percent reduction in LDL cholesterol following high-intensity statin therapy: potential implications for guidelines and for the prescription of emerging lipid-lowering agents.
        Eur Heart J. 2016; 37: 1373-1379
        • Jia X
        • Al Rifai M
        • Ramsey DJ
        • et al.
        Association between lipid testing and statin adherence in the Veterans Affairs health system.
        Am J Med. 2019; 132e693–e700
        • Jia X
        • Ramsey DJ
        • Rifai MA
        • et al.
        Impact of lipid monitoring on treatment intensification of cholesterol lowering therapies (from the Veterans Affairs healthcare system).
        Am J Cardiol. 2020; 125: 874-879
        • Lowenstern AM
        • Li S
        • Navar AM
        • et al.
        Measurement of low-density lipoprotein cholesterol levels in primary and secondary prevention patients: insights from the PALM registry.
        J Am Heart Assoc. 2018; 7e009251